Scientists Discover Genetic “Off Switch” That Supercharges CAR T Cells Against Cancer

Researchers found that disabling NFIL3 made CAR T cells less exhausted and more durable in mouse studies.

Gene editing with CRISPR/Cas9 boosted CAR T-cell persistence, tumor-killing activity, and survival.

The work suggests NFIL3 as a promising target to strengthen CAR T-cell therapy, especially for solid tumors.